TIDES: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Stanley Crooke, M.D, PhD
Chief Executive Officer at Ionis Pharmaceuticals, Inc.

Profile

Dr. Crooke is founder, chairman, and chief executive officer of Ionis Pharmaceuticals. During his tenure at Ionis, he has led the scientific development of a new platform for drug discovery, antisense technology and engineered the creation of one of the largest and more advanced development pipelines in the biotechnology industry. Early in Dr. Crooke’s career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D at SmithKline Beckman. Dr. Crooke has received a number of awards, most recently, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society and the Scrip Lifetime Achievement Award. Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. He has published more than 475 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 22 drugs that have been commercialized.

Stanley Crooke, M.D, PhD's Network

Agenda Sessions

  • Antisense Technology: Today and Tomorrow

    ,